Evidence map›Paper›PMID 31627722›Full record

ArticleBMC neurology2019

Prestroke statins use reduces oxidized low density lipoprotein levels and improves clinical outcomes in patients with atrial fibrillation related acute ischemic stroke.

Lanying He, Ronghua Xu, Jian Wang, Lili Zhang, Lijuan Zhang, Wang Zhao, Weiwei Dong

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 3 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 3 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. The effect of rosuvastatin on cardiogenic cerebral infarction.American journal of translational research · 2021
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Lanying HeDepartment of Neurology, The Second People's Hospital of Chengdu, Chengdu, 610021, People's Republic of China.
Ronghua XuDepartment of Neurosurgery, The Second People's Hospital of Chengdu, Chengdu, 610021, People's Republic of China. 2234117052@qq.com.
Jian WangDepartment of Neurology, The Second People's Hospital of Chengdu, Chengdu, 610021, People's Republic of China.
Lili ZhangDepartment of Neurology, The Second People's Hospital of Chengdu, Chengdu, 610021, People's Republic of China.
Lijuan ZhangDepartment of Neurology, The Second Affiliated Hospital of Chengdu College, Nuclear Industry 416 Hospital, Chengdu, 610021, People's Republic of China.
Wang ZhaoDepartment of Neurology, Yongchuan Hospital, Chongqing Medical University, Chongqing, China, 610020, People's Republic of China.
Weiwei DongDepartment of Neurology, First Affiliated Hospital, Chongqing Medical University, Chongqing, China, 400030, People's Republic of China.
Chengdu Second People's Hospital · CNChongqing Medical University · CN

Funding

The Health and Family Planning Commission of Chengdu 2015009
6 · The paper itself

Abstract

backgroundAtrial fibrillation (AF) is a common cause of cerebral infarction, which could lead to endothelial dysfunction, increased reactive oxygen species (ROS) and oxidized low density lipoprotein (Ox-LDL).AF is associated with higher mortality and more severe neurologic disability. Statins may exert neuroprotective effects that are independent of LDL-C lowering. The purpose of our study was to investigate whether prestroke statins use could reduce plasma Ox-LDL levels and improve clinical outcomes in patients with AF-related acute ischemic stroke (AIS).

methodsThis was a multicenter prospective study that involved four medical centers, 242 AIS patients with AF were identified, who underwent a comprehensive clinical investigation and a 72 h-Holter electrocardiogram monitoring. All patients were divided into two groups: prestroke statins use and no prestroke statins use groups, who were followed up for 3 months. Plasma Ox-LDL levels were measured using enzyme-linked immunosorbent assay (ELISA) on admission and at 3 months. The outcome was death, major disability (modified Rankin Scale score ≥ 3), and composite outcome (death/major disability) at 3 months after AIS.

resultsOne hundred thirty-six patients were in no prestroke statins use group, and 106 in prestroke statins use group. Plasma Ox-LDL levels were significantly lower in prestroke statins use than in no prestroke statins use on admission and at 3 months (P < 0.001). Plasma Ox-LDL levels on admission were associated with 3-month mortality [adjusted odds ratio (OR), 1.05; 95% confidence interval (CI), 0.99-1.12; P = 0.047]. In fully adjusted models, prestroke statins use was associated with reduced 3-month mortality [adjusted OR, 0.38; 95% CI, 0.16-0.91; P = 0.031)], major disability (adjusted OR, 0.38; 95% CI, 0.15-0.99; P = 0.047), and composite outcome (adjusted OR, 0.31; 95% CI, 0.17-0.74; P = 0.009).

conclusionsPrestroke statins use can reduce plasma Ox-LDL levels and improve clinical outcomes in patients with AF-related AIS.

Indexed as

StrokeAgedAged, 80 and overAtrial FibrillationCerebral InfarctionFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLipoproteins, LDLMaleMiddle AgedOdds RatioProspective StudiesHydroxymethylglutaryl-CoA Reductase InhibitorsLipoproteins, LDLoxidized low density lipoproteinAcute ischemic strokeAtrial fibrillationOutcomeOxidized low densityStatins

Identifiers

PMID31627722
PMCPMC6800490
OpenAlexW2981208437

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.